Professor and Vice Chair
Johns Hopkins
Baltimore, Maryland, United States
Dr. Chetan Bettegowda is the Jennison and Novak Families Professor of Neurosurgery and Oncology and Vice Chair for Research in the Department of Neurosurgery at the Johns Hopkins University School of Medicine. He directs the Rheza Khatib Brain Tumor Center at Johns Hopkins and leads the Johns Hopkins Physician Scientist Program. His clinical focus is on the surgical management of brain tumors, while studying the molecular events cause them to arise in the laboratory. In particular, his current research is focused on translating our genetic understanding of tumors for diagnostic benefit. As Medical Director of the Ludwig Center for Cancer Genetics and Therapeutics, his efforts have focused on the applications of cell free tumor derived DNA for the early detection and monitoring of a myriad of cancers. His research is funded by the Burroughs Wellcome Career Award for Medical Scientists, Doris Duke Clinician Scientist Award, Department of Defense and the National Cancer Institute. He has been recognized with numerous awards including being named the William Baumgartner Johns Hopkins Physician of the Year. He has published widely with over 240 articles including in journals such as Science, Science Translational Medicine, Nature Genetics, Nature Communications and PNAS.
Dr. Bettegowda attended Duke University as a Benjamin N. Duke Scholar, where he graduated with a double major in Biology and Religion. He went on to complete his MD and PhD degree in Cellular and Molecular Medicine at the Johns Hopkins University School of Medicine, in the laboratory of Drs. Bert Vogelstein and Ken Kinzler. After finishing the MD/PhD program, Dr. Bettegowda completed his neurosurgery training at Johns Hopkins. While a resident, he returned to the Vogelstein/Kinzler lab to finish a post-doctoral fellowship.
(NC5504) Future of Genomic Classication in GBM
Monday, April 24, 2023
8:25am – 8:44am PST
Disclosure(s): Belay Diagnostics: Board Member/Officer/Trustee (Ongoing), Ownership Interest (Ongoing); Bionaut Labs: Consultant (Ongoing); Depuy-Synthes: Consultant (Ongoing); Galectin Therapeutics: Consultant (Ongoing); Haystack Oncology: Consultant (Ongoing); OrisDx: Board Member/Officer/Trustee (Ongoing), Ownership Interest (Ongoing); Privo Technology: Consultant (Ongoing)
Monday, April 24, 2023
8:25am – 8:41am PST
Disclosure(s): Belay Diagnostics: Board Member/Officer/Trustee (Ongoing), Ownership Interest (Ongoing); Bionaut Labs: Consultant (Ongoing); Depuy-Synthes: Consultant (Ongoing); Galectin Therapeutics: Consultant (Ongoing); Haystack Oncology: Consultant (Ongoing); OrisDx: Board Member/Officer/Trustee (Ongoing), Ownership Interest (Ongoing); Privo Technology: Consultant (Ongoing)
Monday, April 24, 2023
8:42am – 8:58am PST
Disclosure(s): Belay Diagnostics: Board Member/Officer/Trustee (Ongoing), Ownership Interest (Ongoing); Bionaut Labs: Consultant (Ongoing); Depuy-Synthes: Consultant (Ongoing); Galectin Therapeutics: Consultant (Ongoing); Haystack Oncology: Consultant (Ongoing); OrisDx: Board Member/Officer/Trustee (Ongoing), Ownership Interest (Ongoing); Privo Technology: Consultant (Ongoing)
(NC5505) Radiosurgery Is Ticky, but Works…indications, Limitations and Long-term Outcomes
Monday, April 24, 2023
8:59am – 9:15am PST
Disclosure(s): Belay Diagnostics: Board Member/Officer/Trustee (Ongoing), Ownership Interest (Ongoing); Bionaut Labs: Consultant (Ongoing); Depuy-Synthes: Consultant (Ongoing); Galectin Therapeutics: Consultant (Ongoing); Haystack Oncology: Consultant (Ongoing); OrisDx: Board Member/Officer/Trustee (Ongoing), Ownership Interest (Ongoing); Privo Technology: Consultant (Ongoing)
(NC5505) Molecular Strategy to Meningioma
Monday, April 24, 2023
9:16am – 9:32am PST
Disclosure(s): Belay Diagnostics: Board Member/Officer/Trustee (Ongoing), Ownership Interest (Ongoing); Bionaut Labs: Consultant (Ongoing); Depuy-Synthes: Consultant (Ongoing); Galectin Therapeutics: Consultant (Ongoing); Haystack Oncology: Consultant (Ongoing); OrisDx: Board Member/Officer/Trustee (Ongoing), Ownership Interest (Ongoing); Privo Technology: Consultant (Ongoing)
(NC5505) Atypical Meningiomas. Surgery and Radiation
Monday, April 24, 2023
9:33am – 9:49am PST
Disclosure(s): Belay Diagnostics: Board Member/Officer/Trustee (Ongoing), Ownership Interest (Ongoing); Bionaut Labs: Consultant (Ongoing); Depuy-Synthes: Consultant (Ongoing); Galectin Therapeutics: Consultant (Ongoing); Haystack Oncology: Consultant (Ongoing); OrisDx: Board Member/Officer/Trustee (Ongoing), Ownership Interest (Ongoing); Privo Technology: Consultant (Ongoing)
(NC5505) MIS Approaches to Meningioma
Monday, April 24, 2023
9:50am – 10:06am PST
Disclosure(s): Belay Diagnostics: Board Member/Officer/Trustee (Ongoing), Ownership Interest (Ongoing); Bionaut Labs: Consultant (Ongoing); Depuy-Synthes: Consultant (Ongoing); Galectin Therapeutics: Consultant (Ongoing); Haystack Oncology: Consultant (Ongoing); OrisDx: Board Member/Officer/Trustee (Ongoing), Ownership Interest (Ongoing); Privo Technology: Consultant (Ongoing)
(NC5505) AI Advancements in Meningioma
Monday, April 24, 2023
10:07am – 10:23am PST
Disclosure(s): Belay Diagnostics: Board Member/Officer/Trustee (Ongoing), Ownership Interest (Ongoing); Bionaut Labs: Consultant (Ongoing); Depuy-Synthes: Consultant (Ongoing); Galectin Therapeutics: Consultant (Ongoing); Haystack Oncology: Consultant (Ongoing); OrisDx: Board Member/Officer/Trustee (Ongoing), Ownership Interest (Ongoing); Privo Technology: Consultant (Ongoing)